The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Success of Direct-Acting, Antiviral-Based Therapy for Chronic Hepatitis C Is Not Affected by Type 2 Diabetes
Niccum BA1, Stine JG2, Wynter JA3, Kelly V3, Caldwell SH3, Shah NL3. Clin Diabetes. 2020 Jan;38(1):40-46. doi: 10.2337/cd18-0112.
Author information
1 Department of Internal Medicine, Massachusetts General Hospital, Boston, MA.
2 Division of Gastroenterology and Hepatology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA.
3 Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, VA.
Abstract
Chronic hepatitis C virus (HCV) is a risk factor for type 2 diabetes. In the era of interferon-based HCV therapy, type 2 diabetes was associated with decreased likelihood of sustained virologic response (SVR). Preliminary studies suggest that type 2 diabetes may not reduce the efficacy of regimens involving direct-acting antiviral (DAA) medications. We aimed to determine whether preexisting type 2 diabetes is associated with a reduced rate of SVR achieved 12 weeks after treatment of HCV with DAA-based regimens.